Clinical Trials Browser

Has results × Lymphoma, T-Cell, Peripheral × 1 year × Clear all

NCT02362997 2026-05-18

Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL

Phase 2 Completed

82 enrolled 20 charts

Hodgkin Disease, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral

NCT03927105 2026-05-07

Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma

Phase 2 Completed

4 enrolled 15 charts

Lymphoma, T-Cell, Peripheral

NCT03547700 2026-05-06

Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)

Phase 1/2 Terminated

11 enrolled 10 charts

Lymphoma, T-Cell, Peripheral

NCT04569032 2026-02-18

A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

Phase 2 Completed

82 enrolled 13 charts

Lymphoma, T-Cell, Peripheral

NCT04447027 2026-01-30

Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies

Phase 1 Completed

26 enrolled 24 charts

DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT02264613 2026-01-13

ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas

Phase 1/2 Completed

142 enrolled 30 charts

Lymphoma, Lymphoma, T-Cell, Peripheral

NCT04703192 2025-12-09

Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)

Phase 2 Active not recruiting

155 enrolled 11 charts

LymphoidOther hematologic neoplasm

Lymphoma, T-Cell, Peripheral, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT05883449 2025-08-20

LuminICE-203

Phase 2 Terminated

25 enrolled 21 charts

Hodgkin Disease, Recurrence, Lymphoma, T-Cell, Peripheral